Funding for this research was provided by:
Received: 10 September 2020
Accepted: 12 May 2021
First Online: 21 June 2021
: Before recruiting subjects, all study documents were submitted and approved by the National Health Service Central Research Ethics Committee, approval number: 17/WS/0260. This study was conducted in compliance with Good Clinical Practice guidelines, including International Conference on Harmonization Guidelines and consistent with the most recent version of the Declaration of Helsinki. In addition, all applicable local laws and regulatory requirements were adhered to throughout the study.
: Not applicable – all data in publication is anonymized.
: HD, UC, and CH declare that they have no competing interests to disclose. IT is an employee of and a stockholder in Alexion Pharmaceuticals, Inc.